On Oct. 20, 2014, Oregon Health & Science University’s Vaccine & Gene Therapy Institute (OHSU) announced it was awarded a $10 million contract from the National Institute of Allergy and Infectious Diseases.

Kineta, the University of Washington Center for Innate Immunity and Immune Disease, and the Vaccine & Gene Therapy Institute of Florida collaborated with OHSU as major sub-contractors to develop new vaccine adjuvants that could boost the effectiveness of a wide range of human vaccines for infectious diseases including West Nile Virus, Dengue and Japanese Encephalitis.